Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
You're in a hurry, you misplace a decimal
Dizziness or Headache: If severe, stop use and consult a healthcare professional
Where does my order ship from
doi: 10.3389/fcdhc.2026.1772391 Received 20 December 2025 Revised 15 March 2026 Accepted 16 March 2026 Published 10 April 2026 Volume 7 - 2026 Edited by Arrigo Francesco Giuseppe Cicero, University of Bologna, Italy Reviewed by Alessando Mattina, IRRCS ISMETT/UPMC Italy, Italy Updates Copyright 2026 Jdrasek, Lisowska and Czupryniak
Clinicians should actively screen at-risk patients by assessing liver enzymes (ALT, AST), calculating non-invasive scores like FIB-4, and using imaging when necessary
PATIENTS with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may face an increased risk of developing certain autoimmune diseases compared with those on dipeptidyl peptidase-4 inhibitors (DPP-4is), according to new real-world evidence from a large U.S
US$ 29.82
US$ 26.43
US$ 24.10
US$ 24.75
